

# Cancer drug being repurposed to treat Fragile X Syndrome

Posted on Wednesday, May 3, 2017

Researchers at UW-Madison are trying to repurpose an antitumor drug to treat a common intellectual disability known as Fragile X Syndrome.

And Professor Xinyu Zhao, a professor of neuroscience at UW-Madison who's heading up this research, says initial tests in rodents show promise for this experimental treatment option.

"This could be a new way to treat, at least, cognitive function in Fragile X patients — at least worth exploring," Zhao said.

The Wisconsin Alumni Research Foundation is seeking commercial licensing partners for the patent, which covers the use of Nutlin-3, a candidate antitumor drug, to treat Fragile X Syndrome.

See more at [WisBusiness.com](http://WisBusiness.com)